^
Association details:
| Biomarker: | KRAS mutation + STK11 mutation + AXL expression |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + bemcentinib (BGB324) (AXL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells
Published date:
03/15/2022
Excerpt:
...we studied two human LUAD KL-mutated cell lines, A549 and H2122, in a humanized NSG-SGM3 mouse model. Although these cell lines harbor KRAS and STK11/LKB1 mutations...A549 express AXL while H2122 has limited AXL expression...BGB324 sensitized A549 and H2122 tumors in humanized mice to pembrolizumab...
DOI:
https://doi.org/10.1016/j.xcrm.2022.100554
